Identifying  ||| S:0 E:12 ||| NNP
Patient  ||| S:12 E:20 ||| NNP
Candidates  ||| S:20 E:31 ||| NNP
for  ||| S:31 E:35 ||| IN
IL-1  ||| S:35 E:40 ||| NNP
Inhibition ||| S:40 E:50 ||| NNP
:  ||| S:50 E:52 ||| :
Lessons  ||| S:52 E:60 ||| NNP
From  ||| S:60 E:65 ||| IN
Real-World  ||| S:65 E:76 ||| JJ
Cases  ||| S:76 E:82 ||| NNS
A  ||| S:82 E:84 ||| DT
subgroup  ||| S:84 E:93 ||| NN
of  ||| S:93 E:96 ||| IN
patients  ||| S:96 E:105 ||| NNS
with  ||| S:105 E:110 ||| IN
gouty  ||| S:110 E:116 ||| JJ
arthritis  ||| S:116 E:126 ||| NNS
have  ||| S:126 E:131 ||| VBP
a  ||| S:131 E:133 ||| DT
chronic  ||| S:133 E:141 ||| JJ
recurring  ||| S:141 E:151 ||| JJ
form  ||| S:151 E:156 ||| NN
that  ||| S:156 E:161 ||| WDT
is  ||| S:161 E:164 ||| VBZ
particularly  ||| S:164 E:177 ||| RB
difficult  ||| S:177 E:187 ||| JJ
to  ||| S:187 E:190 ||| TO
treat ||| S:190 E:195 ||| VB
.  ||| S:195 E:197 ||| .
Such  ||| S:197 E:202 ||| JJ
patients  ||| S:202 E:211 ||| NNS
experience  ||| S:211 E:222 ||| VBP
repeated  ||| S:222 E:231 ||| VBN
flares  ||| S:231 E:238 ||| NNS
and  ||| S:238 E:242 ||| CC
often  ||| S:242 E:248 ||| RB
have  ||| S:248 E:253 ||| VB
abundant  ||| S:253 E:262 ||| JJ
tophi ||| S:262 E:267 ||| NN
.  ||| S:267 E:269 ||| .
Many  ||| S:269 E:274 ||| JJ
also  ||| S:274 E:279 ||| RB
have  ||| S:279 E:284 ||| VBP
underlying  ||| S:284 E:295 ||| VBG
comorbidities ||| S:295 E:308 ||| NN
,  ||| S:308 E:310 ||| ,
such  ||| S:310 E:315 ||| JJ
as  ||| S:315 E:318 ||| IN
renal  ||| S:318 E:324 ||| JJ
impairment ||| S:324 E:334 ||| NN
,  ||| S:334 E:336 ||| ,
cardiovascular  ||| S:336 E:351 ||| JJ
disease ||| S:351 E:358 ||| NN
,  ||| S:358 E:360 ||| ,
gastrointestinal  ||| S:360 E:377 ||| JJ
disorders ||| S:377 E:386 ||| NNS
,  ||| S:386 E:388 ||| ,
obesity ||| S:388 E:395 ||| NN
,  ||| S:395 E:397 ||| ,
and  ||| S:397 E:401 ||| CC
hypertension ||| S:401 E:413 ||| NN
,  ||| S:413 E:415 ||| ,
which  ||| S:415 E:421 ||| WDT
contraindicate  ||| S:421 E:436 ||| VBZ
the  ||| S:436 E:440 ||| DT
use  ||| S:440 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
standard  ||| S:447 E:456 ||| JJ
anti-inflammatory  ||| S:456 E:474 ||| JJ
medications ||| S:474 E:485 ||| NN
.  ||| S:485 E:487 ||| .
Five  ||| S:487 E:492 ||| CD
patients  ||| S:492 E:501 ||| NNS
with  ||| S:501 E:506 ||| IN
difficult  ||| S:506 E:516 ||| JJ
to  ||| S:516 E:519 ||| TO
treat  ||| S:519 E:525 ||| VB
gouty  ||| S:525 E:531 ||| JJ
arthritis  ||| S:531 E:541 ||| NN
who  ||| S:541 E:545 ||| WP
were  ||| S:545 E:550 ||| VBD
either  ||| S:550 E:557 ||| DT
candidates  ||| S:557 E:568 ||| NNS
and ||| S:568 E:571 ||| CC
/ ||| S:571 E:572 ||| NNP
or  ||| S:572 E:575 ||| CC
treated  ||| S:575 E:583 ||| VBN
with  ||| S:583 E:588 ||| IN
anti-IL  ||| S:588 E:596 ||| JJ
therapy  ||| S:596 E:604 ||| NN
are  ||| S:604 E:608 ||| VBP
described ||| S:608 E:617 ||| VBN
.  ||| S:617 E:619 ||| .
